Floatz logo

OFRANERGENE OBADENOVEC

Glioblastoma

Vascular Biogenics Ltd. operating as VBL Therapeuticsgene_therapyPhase 3Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
65/ 100

Competitive context

354 Active assets in the Glioblastoma cohort.

Asset / SponsorPhaseRating
Irinotecan
Beijing Sanbo Brain Hospital
Phase 2/3BBB
Depatuxizumab Mafodotin
AbbVie
Phase 3BB
CARMUSTINE
Leland Metheny
Phase 3BB
Irinotecan
University of Cincinnati
Phase 3BB
(+)-VINCRISTINE
University of Cincinnati
Phase 3BB

View all 50 →

Same molecule, other indications

OFRANERGENE OBADENOVEC is also rated in:

ovarian cancerDormant
B
Indicative ·
61 / 100
View asset →
Colorectal Cancer With Hepatic MetastasesDormant
CCC
Indicative ·
53 / 100
View asset →
colorectal neoplasmDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →